Uwell Biopharma Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2019	FY 2018
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Net Income	-54.86	-40.87	-45.17	-41.47	-20.48	-16.84
Depreciation & Amortization	7.91	7.51	7.24	7.18	1.78	0.03
Stock-Based Compensation	0.54	-	-	-	-	0.73
Other Operating Activities	-0.02	0.03	-0.06	-	-	-
Change in Accounts Receivable	-	-	-	0.02	-0.06	-
Change in Accounts Payable	7.22	1.53	-1.51	-0.1	1.7	-0.86
Change in Other Net Operating Assets	-0.71	-0.57	-1.13	-0.88	-0.58	-0.73
Operating Cash Flow	-39.91	-32.38	-40.63	-35.24	-17.62	-17.67
Capital Expenditures	-0.47	-	-2.01	-0.62	-1.64	-
Cash Acquisitions	-	-	-	-	-	-6.51
Investment in Securities	40.5	58.5	-63	18	-	-
Other Investing Activities	-1.26	-1.26	0.21	-	-1.25	-
Investing Cash Flow	38.77	57.24	-64.8	17.38	-2.89	-6.51
Long-Term Debt Repaid	-	-4.55	-4.2	-4.19	-1.67	-
Net Debt Issued (Repaid)	-5.04	-4.55	-4.2	-4.19	-1.67	-
Issuance of Common Stock	200	-	105	-	113.2	8.6
Financing Cash Flow	194.97	-4.55	100.81	-4.19	111.53	8.6
Foreign Exchange Rate Adjustments	-0.02	-	0.01	-0	-0.16	-0.05
Net Cash Flow	193.8	20.3	-4.62	-22.05	90.86	-15.62
Free Cash Flow	-40.38	-32.38	-42.64	-35.86	-19.27	-17.67
Free Cash Flow Margin	-8972.67%	-7196.22%	-	-	-	-
Free Cash Flow Per Share	-0.34	-0.28	-0.48	-0.63	-1.17	-2.74
Cash Interest Paid	0.17	0.21	0.22	0.28	0.07	-
Cash Income Tax Paid	0.02	0.01	-	-	-	-
Levered Free Cash Flow	-	-17.99	-26.88	-	-11.7	-
Unlevered Free Cash Flow	-	-17.86	-26.74	-	-11.66	-
Change in Working Capital	6.51	0.96	-2.64	-0.95	1.07	-1.59

Source: S&P Global Market Intelligence. Standard template. Financial Sources.